Back to Journals » Vascular Health and Risk Management » Volume 2 » Issue 4

Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI)

Authors Huyen Tran, Shamir R Mehta, John W Eikelboom

Published 15 December 2006 Volume 2006:2(4) Pages 379—387


Huyen Tran1, Shamir R Mehta2, John W Eikelboom2

1Department of Clinical Haematology, Monash Medical Centre, Victoria, Australia; 2Department of Medicine, McMaster University, Hamilton, Canada

Abstract: The pathogenesis of ST-elevation myocardial infarction (STEMI) involves plaque disruption, platelet aggregation and intracoronary artery thrombus formation. Aspirin is the cornerstone of antiplatelet therapy in patients with STEMI, reducing the risk of recurrent myocardial infarction or death during the acute phase and long term by about one-quarter. Recent large randomized trials have demonstrated that the addition of clopidogrel to aspirin reduces the risk of major ischemic events by up to a further one-third in patients with STEMI treated with fibrinolytic therapy and undergoing percutaneous coronary intervention, with no significant increase in bleeding. Thus, dual antiplatelet therapy with the combination of clopidogrel and aspirin is becoming the new standard of care for the management of patients with STEMI.

Keywords: clopidogrel, antiplatelet drugs, acute coronary syndrome, myocardial infarction

Download Article [PDF]